Education ▼

SPECIALTY TOPICS

CURRENTLY VIEWING
Immunotherapy in Melanoma

Breast Cancer

Gastrointestinal Cancer

Colorectal Cancer

Ovarian Cancer

Prostate Cancer

Precision Medicine in Oncology^®

Neoadjuvant HER2+

More >>

Immunotherapy in Melanoma

Checkpoint Inhibitors Vault Into Frontline Settings Across Tumor Types

By the end of 2018, the 57 oncology drugs launched from 2014 to 2018 had gained 89 indications across 23 cancer types. These new agents included numerous checkpoint inhibitors, which saw tremendous uptake based on their ability to dramatically improve...
Read More >>

NY-ESO-1 Gains Momentum as a Therapeutic Target

FDA Grants Bempegaldesleukin Plus Nivolumab Breakthrough Designation in Melanoma

Smoking, Vitamin D Deficiency Correlate to Ulcerated Melanoma

ctDNA Monitoring Carries Clinical Validity in Advanced BRAF-Mutant Melanoma

Long Shares Insight on Pivotal Data in BRAF-Mutant Melanoma

View More Stories >>

View Conference Coverage

Charlotte Plasma Cell Disorder Congress

State of the Science Summit on Breast Cancer in Long Island

2019 International Lung Cancer Congress

2019 State of the Science Summit on Genitourinary Cancers in Jacksonville

2019 State of the Science Summit on Hematologic Malignancies in Pittsburgh

Dr. Atkins on Long-Term Survival Benefit of Nivolumab/Ipilimumab in Advanced Melanoma

Dr. Flaherty on the Rationale to Explore Triplet Therapy in BRAF V600E-Mutant Melanoma

Dr. Nathan on 5-Year Survival Outcomes of COMBI-d and COMBI-v Trials in BRAF V600-Mutant Melanoma

Dr. Polsky on the Predictive Value of ctDNA in BRAF-Mutant Melanoma

Dr. Long on Dabrafenib/Trametinib in BRAF V600E-Mutant Melanoma

OncLive houses thousands of videos that provide updates and information.
See more Videos

Unmet Needs and Future Treatments of Metastatic Melanoma

The Use of Dual Targeted Therapy in Metastatic Melanoma

$Management of Relapsed/Refractory Metastatic Melanoma$

Management of Relapsed/Refractory Metastatic Melanoma

Immunotherapy vs TKIs in BRAF+ Metastatic Melanoma

Management of Patients with BRAF-Mutated Melanoma

OncLive houses thousands of videos that provide updates and information.
See more Videos

Trials and Treatment in Advanced Melanoma

Recommendations for Molecular Testing in Melanoma

BRAF and MEK in Melanoma

Developments in the Management of Stage III Melanoma

Emerging Approaches for BRAF-Mutant Metastatic Melanoma

Treatment Sequencing in BRAF+ Metastatic Melanoma

Treatment Adherence and Response With BRAF-Targeted Therapy

OncLive houses thousands of videos that provide updates and information.
See more Videos

Featured Programs

Metastatic Melanoma: The New Millennium

Keith Flaherty, MD, moderates this discussion with Rene Gonzalez, MD, Jason Luke, MD, FACP, and Jeffrey Weber, MD, PhD. The panel of experts in melanoma research and treatment talk about the most recent advances in the field, and provide perspective on how to apply the newest data to individualize treatment strategies.

View Now

Dr. Hodi on Long-Term Survival Data for Nivolumab in Melanoma

F. Stephen Hodi, MD, director of the Melanoma Center at Dana-Farber Cancer Institute, and investigator at the Ludwig Center at Harvard, discusses the results of a 5-year follow-up analysis of survival outcomes of patients with advanced melanoma who were treated with single-agent nivolumab (Opdivo).

View Now

Featured Video

Dr. Richardson Discusses New Directions in Multiple Myeloma

Paul G. Richardson, MD, clinical program leader and director of clinical research, Jerome Lipper Multiple Myeloma Center, and institute physician, Dana-Farber Cancer Institute, discusses new directions in multiple myeloma. View now

Priority Review Designation in GIST, Promising Findings in Bladder Cancer and NSCLC, and More